ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Exercise Tests Suggest Autoimmunity Causes the Exertion Problems in Chronic Fatigue Syndrome, Fibrom...

Not Just an "Ill Person" - Ways to expand your identity when you're chronically ill

Is Poor Sleep Pummeling the Immune System in ME/CFS and Fibromyalgia? A Vicious Circle Examined

Is Chronic Fatigue Real?

Taking a Moment

VIDEO: Illness and Isolation

Staying Connected with Friends While Ill

Inflammation correlates with symptoms in chronic fatigue syndrome

Recognizing the Needs of Pain Patients in Substance Use Policy

Call Out the Imbalance in Current Policy Making for Pain Management and Prescription Opioid Use

 
Print Page
Email Article

Long-Term Effects of Savella for Fibromyalgia Evaluated

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 4, 2013


Article:

A 3-Year, Open-Label, Flexible-Dosing Study of Milnacipran for the Treatment of Fibromyalgia.
– Source: The Clinical Journal of Pain, February 26, 2013

By L.M. Arnold, R.H. Palmer and Y. Ma

Abstract:

OBJECTIVES: To evaluate the effects of long-term milnacipran [brand name Savella] treatment in fibromyalgia patients.

METHODS:
Patients completing a previous milnacipran study were eligible to participate in this long-term (up to 3.25 y), open-label study. After washout, dose escalation, and 8 weeks of stable-dose treatment (100 mg/d), patients received flexible doses of milnacipran (50 to 200 mg/d) for the remainder of the study.

Safety evaluations included adverse events and vital signs. Clinical measures included weekly recall pain [visual analog scale (VAS)], Patient Global Disease Status (PGDS), and the Short Form-36 Health Survey [SF-36, including the Physical Component Summary (PCS) and Mental Component Summary scores]. Cohort analyses were conducted to assess the effects of milnacipran over varying periods of time.

RESULTS: Of 1227 patients entering the study, 585 (47.7%) were classified as completers, including 379 (30.9%) patients who were currently enrolled when the study was administratively terminated. Mean duration of treatment was 19 months, with 206 patients reaching the final visit and receiving 36 to 38 months of study treatment.

  • The percentage of patients with ?1 treatment-emergent adverse event was 88.3%, with nausea (25.9%) and headache (13.4%) being the most common events.

  • Discontinuations due to adverse events occurred in 20.9% of patients.

  • Potentially clinically significant increases in blood pressure or heart rate occurred in ?1.1% of patients.

  • Mean improvement from baseline in weekly recall VAS pain was 17.6; improvements in global status (PGDS) and physical functioning (SF-36 PCS) were also observed.

  • In all patient cohorts, these improvements were observed by month 3 and remained relatively constant over time.

  • At final study visit in the 3-year cohort, 70.3% of patients rated their overall fibromyalgia as "much improved" or "very much improved."

DISCUSSION: No new safety concerns were identified in this long-term study. Sustained symptom improvements were found in fibromyalgia patients who received up to 3.25 years of milnacipran treatment.


Source: The Clinical Journal of Pain, February 26, 2013. By L.M. Arnols, R.H. Palmer and Y. Ma. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH; Forest Research Institute Inc., Jersey City, NJ.





Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength MitoQ® B-12 Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging
Vital Molecule Increases Cellular Energy and Improves Cognitive Function Vital Molecule Increases Cellular Energy and Improves Cognitive Function
Eating Fat is Good... Maybe... Could Be... Sometimes Eating Fat is Good... Maybe... Could Be... Sometimes
The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS The Crucial Role CoQ10 Plays in Fibromyalgia and ME/CFS
Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing Rejuvenating the Brain - How PQQ Helps Power Up Mental Processing

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map